Lung Cancer Biopsy: Can Diagnosis Be Changed After Immunohistochemistry when the H&E-Based Morphology Corresponds to a Specific Tumor Subtype?

Overview

Journal Clinics (Sao Paulo)

Publisher Elsevier

Specialty General Medicine

Date 2018 Nov 1

PMID 30379223

Citations 6

Authors

Fabiola Del Carlo Bernardi

Marcela Del Carlo Bernardi

Teresa Takagaki

Sheila Aparecida Coelho Siqueira

Marisa Dolhnikoff

Affiliations

Soon will be listed here.

Abstract

Objectives: Advancements in non-small cell lung cancer treatment based on targeted therapies have made the differentiation between adenocarcinoma and squamous cell carcinoma increasingly important. Pathologists are challenged to make the correct diagnosis in small specimens. We studied the accuracy of an immunohistochemical panel in subclassifying non-small cell lung cancer in routine small biopsies and compared the results with the diagnosis from resected lung specimens, autopsy samples or biopsied/resected metastases.

Methods: In total, 340 lung cancer biopsies were investigated for the expression of CK5, TTF1, p63 and surfactant.

Results: We characterized 166 adenocarcinomas and 124 squamous cell carcinomas. Overall, 85% of cases displayed binary staining (TTF1 positive/p63 negative, and vice versa). The diagnoses of ten cases with a morphology that indicated a specific tumor subtype were changed after immunohistochemistry (IHC). A second specimen was available for 71 patients, and the first diagnosis at biopsy was confirmed in 95% of these cases. Most non-small cell lung cancer cases present a binary immunohistochemical profile in small biopsies, contributing to good diagnostic accuracy with routine markers. In a small proportion of cases, the diagnosis can be changed after IHC even when the morphological aspects indicate one specific tumor subtype.

Conclusions: We recommend that routine small biopsies of lung cancer without classic morphology should be subjected to a minimum immunohistochemical panel to differentiate adenocarcinoma from squamous cell carcinoma.

Citing Articles

Cell Membrane Coated pH-Responsive Intelligent Bionic Delivery Nanoplatform for Active Targeting in Photothermal Therapy.

Zhang X, He Z Int J Nanomedicine. 2023; 18:7729-7744.

PMID: 38115989 PMC: 10729683. DOI: 10.2147/IJN.S436940.

Acute myocardial infarction due to coronary embolism caused by a metastatic mass from lung cancer.

Zhao Y, Mao M, Zhang N, Zhang S, Niku W, Zhu L BMC Cardiovasc Disord. 2023; 23(1):461.

PMID: 37710181 PMC: 10503072. DOI: 10.1186/s12872-023-03505-3.

Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management.

Sutic M, Vukic A, Baranasic J, Forsti A, Dzubur F, Samarzija M J Pers Med. 2021; 11(11).

PMID: 34834454 PMC: 8624402. DOI: 10.3390/jpm11111102.

The value of AGR2 and KRT5 as an immunomarker combination in distinguishing lung squamous cell carcinoma from adenocarcinoma.

Pan B, Wei Z, Zhang J, Li X, Meng Q, Cao Y Am J Transl Res. 2021; 13(5):4464-4476.

PMID: 34150027 PMC: 8205719.

A deep learning model for the classification of indeterminate lung carcinoma in biopsy whole slide images.

Kanavati F, Toyokawa G, Momosaki S, Takeoka H, Okamoto M, Yamazaki K Sci Rep. 2021; 11(1):8110.

PMID: 33854137 PMC: 8046816. DOI: 10.1038/s41598-021-87644-7.

References

Pelosi G, Scarpa A, Forest F, Sonzogni A . The impact of immunohistochemistry on the classification of lung tumors. Expert Rev Respir Med. 2016; 10(10):1105-21. DOI: 10.1080/17476348.2017.1235975. View

Pelosi G, Fabbri A, Tamborini E, Perrone F, Testi A, Settanni G . Challenging Lung Carcinoma with Coexistent ΔNp63/p40 and Thyroid Transcription Factor-1 Labeling Within the Same Individual Tumor Cells. J Thorac Oncol. 2015; 10(10):1500-2. DOI: 10.1097/JTO.0000000000000553. View

Nicholson A, Gonzalez D, Shah P, Pynegar M, Deshmukh M, Rice A . Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol. 2010; 5(4):436-41. DOI: 10.1097/JTO.0b013e3181c6ed9b. View

Zachara-Szczakowski S, Verdun T, Churg A . Accuracy of classifying poorly differentiated non-small cell lung carcinoma biopsies with commonly used lung carcinoma markers. Hum Pathol. 2015; 46(5):776-82. DOI: 10.1016/j.humpath.2015.02.001. View

Petrosyan F, Daw H, Haddad A, Spiro T . Targeted therapy for lung cancer. Anticancer Drugs. 2012; 23(10):1016-21. DOI: 10.1097/CAD.0b013e3283585149. View

Scagliotti G, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C . Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26(21):3543-51. DOI: 10.1200/JCO.2007.15.0375. View

Travis W, Brambilla E, Burke A, Marx A, Nicholson A . Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol. 2015; 10(9):1240-1242. DOI: 10.1097/JTO.0000000000000663. View

Travis W, Lubin J, Ries L, Devesa S . United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer. 1996; 77(12):2464-70. DOI: 10.1002/(SICI)1097-0142(19960615)77:12<2464::AID-CNCR8>3.0.CO;2-M. View

Terry J, Leung S, Laskin J, Leslie K, Gown A, Ionescu D . Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol. 2010; 34(12):1805-11. DOI: 10.1097/PAS.0b013e3181f7dae3. View

10.

Warth A, Muley T, Herpel E, Meister M, Herth F, Schirmacher P . Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. Histopathology. 2012; 61(6):1017-25. DOI: 10.1111/j.1365-2559.2012.04308.x. View

11.

Monica V, Ceppi P, Righi L, Tavaglione V, Volante M, Pelosi G . Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol. 2009; 22(5):709-17. DOI: 10.1038/modpathol.2009.30. View

12.

Walia R, Jain D, Madan K, Sharma M, Mathur S, Mohan A . p40 & thyroid transcription factor-1 immunohistochemistry: A useful panel to characterize non-small cell lung carcinoma-not otherwise specified (NSCLC-NOS) category. Indian J Med Res. 2017; 146(1):42-48. PMC: 5719606. DOI: 10.4103/ijmr.IJMR_1221_15. View

13.

Rekhtman N, Ang D, Sima C, Travis W, Moreira A . Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol. 2011; 24(10):1348-59. DOI: 10.1038/modpathol.2011.92. View

14.

Tran L, Mattsson J, Nodin B, Jonsson P, Planck M, Jirstrom K . Various Antibody Clones of Napsin A, Thyroid Transcription Factor 1, and p40 and Comparisons With Cytokeratin 5 and p63 in Histopathologic Diagnostics of Non-Small Cell Lung Carcinoma. Appl Immunohistochem Mol Morphol. 2015; 24(9):648-659. DOI: 10.1097/PAI.0000000000000235. View

15.

Pelosi G, Fabbri A, Bianchi F, Maisonneuve P, Rossi G, Barbareschi M . ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol. 2011; 7(2):281-90. DOI: 10.1097/JTO.0b013e31823815d3. View

16.

Cadioli A, Rossi G, Costantini M, Cavazza A, Migaldi M, Colby T . Lung cancer histologic and immunohistochemical heterogeneity in the era of molecular therapies: analysis of 172 consecutive surgically resected, entirely sampled pulmonary carcinomas. Am J Surg Pathol. 2014; 38(4):502-9. DOI: 10.1097/PAS.0000000000000154. View